Physician profile
Sunguk Nathan Jang
NPI 1134140577
$64,008.30
in general payments reported to CMS, 2019-2025
22 companies · $25K in 2025
The $25K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $421 · 2021: $3,215 · 2022: $9,524 · 2023: $3,560 · 2024: $11K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Food and Beverage: $4,041 · Travel and Lodging: $3,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,110.99 |
| Food and Beverage | $4,041.00 |
| Travel and Lodging | $3,391.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Endoscopy | $34,110.99 | 2021-2025 | |
| Boston Scientific Corporation | $24,921.01 | 2019-2025 | General - Endochoice, Spyglass, Exalt Model D |
| Celltrion, INC. | $2,072.42 | 2025 | |
| Steris Corporation | $1,227.31 | 2021-2025 | |
| Abbvie INC. | $350.10 | 2021-2025 | |
| Fujifilm Healthcare Americas Corporation | $237.45 | 2024 | Fujifilm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.85 | 2019-2025 | Xifaxan |
| Braintree Laboratories, INC. | $143.95 | 2024 | Suflave, Sutab |
| Covidien Lp | $136.17 | 2019 | |
| Madrigal Pharmaceuticals | $124.93 | 2025 | Rezdiffra |
| Olympus America INC. | $122.63 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $89.57 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $54.33 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $47.86 | 2023 | |
| Celltrion USA INC. | $38.83 | 2025 | Vegzelma |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $27.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.36 | 2022 | |
| Genzyme Corporation | $23.40 | 2024 | |
| Sandoz INC. | $22.09 | 2023 | Hyrimoz |
| Celgene Corporation | $18.35 | 2024 | Zeposia |
| Cook Medical LLC | $14.40 | 2025 | Zenith |
| Vivus LLC | $13.83 | 2025 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunguk Jang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.